{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:29:04Z","timestamp":1792985344205,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Elorac","award":["NCT02811783"],"award-info":[{"award-number":["NCT02811783"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.det.2018.02.011","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T06:22:08Z","timestamp":1529302928000},"page":"245-258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Pruritus in Cutaneous T-Cell Lymphoma and Its\u00a0Management"],"prefix":"10.1016","volume":"36","author":[{"given":"Linda","family":"Serrano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Estela","family":"Martinez-Escala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong A.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Guitart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.det.2018.02.011_bib1","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1529-8019.2010.01366.x","article-title":"Chronic pruritus: a paraneoplastic sign","volume":"23","author":"Yosipovitch","year":"2010","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.det.2018.02.011_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-4632.2009.04249.x","article-title":"New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma","volume":"49","author":"Wang","year":"2010","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2018.02.011_bib3","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1001\/archderm.144.6.738","article-title":"Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma","volume":"144","author":"Gerami","year":"2008","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.det.2018.02.011_bib4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jaad.2016.03.009","article-title":"New insights into folliculotropic mycosis fungoides (FMF): a single-center experience","volume":"75","author":"Hodak","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2018.02.011_bib5","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1001\/archdermatol.2010.101","article-title":"Folliculotropic mycosis fungoides: single-center study and systematic review","volume":"146","author":"Lehman","year":"2010","journal-title":"Arch Dermatol"},{"issue":"8","key":"10.1016\/j.det.2018.02.011_bib6","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1365-4632.2011.05188.x","article-title":"Prevalence and severity of pruritus in cutaneous T cell lymphoma","volume":"51","author":"Vij","year":"2012","journal-title":"Int J Dermatol"},{"issue":"10","key":"10.1016\/j.det.2018.02.011_bib7","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.det.2018.02.011_bib8","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jpainsymman.2012.01.012","article-title":"Prevalence and severity of pruritus and quality of life in patients with cutaneous T-cell lymphoma","volume":"45","author":"Wright","year":"2013","journal-title":"J\u00a0Pain Symptom Manage"},{"issue":"10","key":"10.1016\/j.det.2018.02.011_bib9","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/cncr.22252","article-title":"Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey","volume":"107","author":"Demierre","year":"2006","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.det.2018.02.011_bib10","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1365-2133.2008.08992.x","article-title":"Quality of life and psychological distress in patients with cutaneous lymphoma","volume":"160","author":"Sampogna","year":"2009","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2018.02.011_bib11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2222.2011.03791.x","article-title":"Basic mechanisms of itch","volume":"42","author":"Potenzieri","year":"2012","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.det.2018.02.011_bib12","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/CCO.0000000000000243","article-title":"Tumor microenvironment in mycosis fungoides and Sezary syndrome","volume":"28","author":"Rubio Gonzalez","year":"2016","journal-title":"Curr Opin Oncol"},{"issue":"4","key":"10.1016\/j.det.2018.02.011_bib13","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jaad.2011.12.021","article-title":"Pruritus in cutaneous T-cell lymphoma: a review","volume":"67","author":"Ahern","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.det.2018.02.011_bib14","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood-2012-03-415638","article-title":"Mast cells play a protumorigenic role in primary cutaneous lymphoma","volume":"120","author":"Rabenhorst","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.det.2018.02.011_bib15","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/BF00374079","article-title":"Itch and inflammation induced by intradermally injected interleukin-2 in atopic dermatitis patients and healthy subjects","volume":"287","author":"Wahlgren","year":"1995","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"10.1016\/j.det.2018.02.011_bib16","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jaad.2010.02.062","article-title":"The use of cyclosporine in dermatology: part II","volume":"63","author":"Ryan","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2018.02.011_bib17","doi-asserted-by":"crossref","first-page":"616","DOI":"10.2340\/00015555-0978","article-title":"Sudden onset of an aggressive cutaneous lymphoma in a young patient with psoriasis: role of immunosuppressants","volume":"90","author":"Quereux","year":"2010","journal-title":"Acta Derm Venereol"},{"issue":"10013","key":"10.1016\/j.det.2018.02.011_bib18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0140-6736(15)00389-X","article-title":"Dupilumab: a milestone in the treatment of atopic dermatitis","volume":"387","author":"Tsianakas","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.det.2018.02.011_bib19","doi-asserted-by":"crossref","first-page":"894","DOI":"10.2340\/00015555-2417","article-title":"Cutaneous T-cell lymphoma and pruritus: the expression of IL-31 and its receptors in the skin","volume":"96","author":"Nattkemper","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"10.1016\/j.det.2018.02.011_bib20","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00403-014-1527-x","article-title":"Analysis of the IL-31 pathway in Mycosis fungoides and Sezary syndrome","volume":"307","author":"Mobs","year":"2015","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"10.1016\/j.det.2018.02.011_bib21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jdermsci.2014.02.009","article-title":"Distribution of IL-31 and its receptor expressing cells in skin of atopic dermatitis","volume":"74","author":"Kato","year":"2014","journal-title":"J\u00a0Dermatol Sci"},{"issue":"2","key":"10.1016\/j.det.2018.02.011_bib22","doi-asserted-by":"crossref","first-page":"645","DOI":"10.4049\/jimmunol.1301836","article-title":"Human Th2 but not Th9 cells release IL-31 in a STAT6\/NF-kappaB-dependent way","volume":"193","author":"Maier","year":"2014","journal-title":"J\u00a0Immunol"},{"issue":"4","key":"10.1016\/j.det.2018.02.011_bib23","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jaci.2006.07.015","article-title":"Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis","volume":"118","author":"Neis","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.det.2018.02.011_bib24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2340\/00015555-1191","article-title":"IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis","volume":"92","author":"Nobbe","year":"2012","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"10.1016\/j.det.2018.02.011_bib25","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: a new link between T cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.det.2018.02.011_bib26","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1159\/000323905","article-title":"Staphylococcal alpha-toxin induces a higher T cell proliferation and interleukin-31 in atopic dermatitis","volume":"156","author":"Niebuhr","year":"2011","journal-title":"Int Arch Allergy Immunol"},{"issue":"12","key":"10.1016\/j.det.2018.02.011_bib27","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1038\/jid.2013.227","article-title":"IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus","volume":"133","author":"Singer","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.det.2018.02.011_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clim.2015.02.014","article-title":"Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities","volume":"158","author":"Cedeno-Laurent","year":"2015","journal-title":"Clin Immunol"},{"issue":"9","key":"10.1016\/j.det.2018.02.011_bib29","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/jid.2010.128","article-title":"Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma","volume":"130","author":"Miyagaki","year":"2010","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.det.2018.02.011_bib30","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2340\/00015555-1428","article-title":"Association of nerve growth factor, chemokine (C-C motif) ligands and immunoglobulin E with pruritus in cutaneous T-cell lymphoma","volume":"93","author":"Suga","year":"2013","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"10.1016\/j.det.2018.02.011_bib31","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s004030000149","article-title":"Immunolocalization of substance P in human skin mast cells","volume":"292","author":"Toyoda","year":"2000","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"10.1016\/j.det.2018.02.011_bib32","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S0022-3565(24)37703-1","article-title":"Substance P induction of itch-associated response mediated by cutaneous NK1 tachykinin receptors in mice","volume":"286","author":"Andoh","year":"1998","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.det.2018.02.011_bib33","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1046\/j.1468-3083.2001.00259.x","article-title":"Modulation of substance P and somatostatin receptors in cutaneous lymphocytic inflammatory and tumoral infiltrates","volume":"15","author":"Misery","year":"2001","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.det.2018.02.011_bib34","first-page":"852","article-title":"Absence of full-length neurokinin-1 receptor protein expression by cutaneous T cells: implications for substance P-mediated signaling in mycosis fungoides","volume":"95","author":"Tuzova","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.det.2018.02.011_bib35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/1346-8138.14033","article-title":"Serum vascular endothelial growth factor A levels reflect itch severity in mycosis fungoides and Sezary syndrome","volume":"45","author":"Sakamoto","year":"2018","journal-title":"J\u00a0Dermatol"},{"issue":"10","key":"10.1016\/j.det.2018.02.011_bib36","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1074\/jbc.M009705200","article-title":"Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells","volume":"276","author":"Kim","year":"2001","journal-title":"J\u00a0Biol Chem"},{"issue":"2","key":"10.1016\/j.det.2018.02.011_bib37","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/jdv.13905","article-title":"Increased serum levels of vascular endothelial growth factor in pemphigus foliaceus patients with erythroderma","volume":"31","author":"Miyamoto","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.det.2018.02.011_bib38","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2133.2008.08612.x","article-title":"Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sezary syndrome","volume":"159","author":"Talpur","year":"2008","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2018.02.011_bib39","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/bjd.12644","article-title":"What are the supportive and palliative care needs of patients with cutaneous T-cell lymphoma and their caregivers? A systematic review of the evidence","volume":"170","author":"Beynon","year":"2014","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2018.02.011_bib40","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2340\/00015555-1246","article-title":"Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus","volume":"92","author":"Phan","year":"2012","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"10.1016\/j.det.2018.02.011_bib41","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1365-2702.2005.01121.x","article-title":"Pain: a review of three commonly used pain rating scales","volume":"14","author":"Williamson","year":"2005","journal-title":"J\u00a0Clin Nurs"},{"issue":"3","key":"10.1016\/j.det.2018.02.011_bib42","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2340\/00015555-1972","article-title":"Comparative cut-off value setting of pruritus intensity in visual analogue scale and verbal rating scale","volume":"95","author":"Kido-Nakahara","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.det.2018.02.011_bib43","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2340\/00015555-1265","article-title":"Visual analogue scale: evaluation of the instrument for the assessment of pruritus","volume":"92","author":"Reich","year":"2012","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.det.2018.02.011_bib44","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jopan.2009.01.010","article-title":"Correlating an 11-point verbal numeric rating scale to a 4-point verbal rating scale in the measurement of pruritus","volume":"24","author":"Jenkins","year":"2009","journal-title":"J\u00a0Perianesth Nurs"},{"issue":"7","key":"10.1016\/j.det.2018.02.011_bib45","doi-asserted-by":"crossref","first-page":"978","DOI":"10.2340\/00015555-2433","article-title":"Itch assessment with visual analogue scale and numerical rating scale: determination of minimal clinically important difference in chronic itch","volume":"96","author":"Reich","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.det.2018.02.011_bib46","first-page":"665","article-title":"Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma","volume":"164","author":"Booken","year":"2011","journal-title":"Br J Dermatol"},{"issue":"29","key":"10.1016\/j.det.2018.02.011_bib47","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.det.2018.02.011_bib48","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2340\/00015555-1446","article-title":"Verbalizing extremes of the visual analogue scale for pruritus: a consensus statement","volume":"93","author":"Furue","year":"2013","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"10.1016\/j.det.2018.02.011_bib49","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jaad.2008.04.006","article-title":"A\u00a0pilot quality-of-life instrument for pruritus","volume":"59","author":"Desai","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2018.02.011_bib50","doi-asserted-by":"crossref","first-page":"562","DOI":"10.2340\/00015555-1544","article-title":"German version of ItchyQoL: validation and initial clinical findings","volume":"93","author":"Krause","year":"2013","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.det.2018.02.011_bib51","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2340\/00015555-2782","article-title":"Assessment of quality of life in chronic pruritus: relationship between ItchyQoL and dermatological life quality index in 1,150 patients","volume":"98","author":"Stumpf","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"10.1016\/j.det.2018.02.011_bib52","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamadermatol.2013.7696","article-title":"Factors mediating the impact of chronic pruritus on quality of life","volume":"150","author":"Carr","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.det.2018.02.011_bib53","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bjd.13732","article-title":"'We had to change to single beds because I itch in the night': a qualitative study of the experiences, attitudes and approaches to coping of patients with cutaneous T-cell lymphoma","volume":"173","author":"Beynon","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2018.02.011_bib54","unstructured":"Network NCC. T-cell lymphomas (Version 1.2018). 2018."},{"issue":"3","key":"10.1016\/j.det.2018.02.011_bib55","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jaad.2006.04.025","article-title":"Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma","volume":"55","author":"Demierre","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.det.2018.02.011_bib56","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1007\/s00105-004-0802-8","article-title":"Antipruritic therapy with the oral opioid receptor antagonist naltrexone. Open, non-placebo controlled administration in 133 patients","volume":"55","author":"Brune","year":"2004","journal-title":"Hautarzt"},{"issue":"1","key":"10.1016\/j.det.2018.02.011_bib57","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12885-017-3194-8","article-title":"Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature","volume":"17","author":"Song","year":"2017","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.det.2018.02.011_bib58","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/archderm.141.3.305","article-title":"Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy","volume":"141","author":"Querfeld","year":"2005","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.det.2018.02.011_bib59","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","article-title":"Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides","volume":"149","author":"Lessin","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.det.2018.02.011_bib60","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0190-9622(03)01475-0","article-title":"Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial","volume":"49","author":"Heald","year":"2003","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2018.02.011_bib61","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3109\/10428194.2012.711829","article-title":"Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin","volume":"54","author":"Kim","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.det.2018.02.011_bib62","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.det.2018.02.011_bib63","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ejca.2012.08.017","article-title":"Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: results of a phase II trial","volume":"49","author":"Duvic","year":"2013","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.det.2018.02.011_bib64","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.13222","article-title":"A\u00a0Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma","volume":"168","author":"Foss","year":"2015","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.det.2018.02.011_bib65","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjd.14427","article-title":"Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides\/Sezary syndrome","volume":"175","author":"Child","year":"2016","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2018.02.011_bib66","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.det.2018.02.011_bib67","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jaad.2006.10.033","article-title":"Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma","volume":"56","author":"Sepmeyer","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2018.02.011_bib68","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/annonc\/mdt480","article-title":"Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma","volume":"25","author":"Straus","year":"2014","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.det.2018.02.011_bib69","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.det.2018.02.011_bib70","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1067\/mjd.2002.124069","article-title":"Effect of insulin-dependent diabetes mellitus on response to extracorporeal photopheresis in patients with Sezary syndrome","volume":"47","author":"Bouwhuis","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.det.2018.02.011_bib71","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1182\/blood-2006-12-062877","article-title":"Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma","volume":"109","author":"Kim","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.det.2018.02.011_bib72","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","article-title":"Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma","volume":"125","author":"Duvic","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.det.2018.02.011_bib73","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.det.2018.02.011_bib74","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.det.2018.02.011_bib75","first-page":"2093","article-title":"Anti-interleukin-31 receptor A antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.det.2018.02.011_bib76","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3109\/10428194.2012.656625","article-title":"Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in\u00a0vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor\/retinoid X receptor activation by histone deacetylase inhibition","volume":"53","author":"Dummer","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.det.2018.02.011_bib77","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.det.2018.02.011_bib78","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3816\/CLM.2002.n.003","article-title":"Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK)","volume":"2","author":"Duvic","year":"2002","journal-title":"Clin Lymphoma"},{"issue":"4","key":"10.1016\/j.det.2018.02.011_bib79","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/13543784.2017.1291630","article-title":"Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study","volume":"26","author":"Espinoza-Zamora","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"10.1016\/j.det.2018.02.011_bib80","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1034\/j.1600-0609.2003.00143.x","article-title":"Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab","volume":"71","author":"Kennedy","year":"2003","journal-title":"Eur J Haematol"},{"issue":"21","key":"10.1016\/j.det.2018.02.011_bib81","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863518300226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863518300226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T04:43:54Z","timestamp":1751690634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863518300226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0733863518300226"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2018.02.011","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pruritus in Cutaneous T-Cell Lymphoma and Its\u00a0Management","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2018.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}